Arbutus announces retirement of chief scientific officer, michael j. sofia, phd, effective december 31, 2024

Warminster, pa., may 02, 2024 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) (“arbutus” or the “company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis b virus (chbv) infection, today announced that after a distinguished 38-year career, the company's co-founder and chief scientific officer, dr. michael sofia, will retire effective december 31, 2024. dr. sofia is a globally recognized, lasker award-winning antiviral drug discovery and development scientist.
ABUS Ratings Summary
ABUS Quant Ranking